The Nucleic Acid Core Facility is located in the Department of Gastrointestinal Oncology and Digestive Diseases in a 500 feet/2 laboratory. The Facility was created in the fall of 1996 through a CCSG supplement in Human Cancer Genetics. The NACF is a centralized facility for extraction of high-quality DNA from peripheral blood leukocytes and cell lines by using an Applied Biosystems Model 341 Nucleic Acid Extractor. This allows for the rapid isolation of highly purified, high- molecular-weight DNA. M.D. Anderson Cancer Center has a wealth of patient and family resources for studies of cancer-susceptibility genes. Most DNA isolation techniques used by individual laboratories required significant technical support and take 3 or more days. A centralized automated facility capable of producing PCR-grade DNA overnight from peripheral blood or cell is a major improvement in efficiency. The facility will be expanded to provide PCR-based genetic testing of transgenic animals. Because the high degree of product purity provided by the Model 341 Nucleic Acid Extractor will not be necessary for this testing, a more crude but rapid extraction procedure will be used to isolate DNA from mouse tails. The DNA will be subjected to PCR by using primates specifically designed to detect the transgenes, and animals positive for the transgenes will be identified. A large number of transgenic animal lines from over 20 different laboratories at M.D. Anderson are currently under investigation. Conducting DNA extraction from transgenic animal tails and PCR-based genetic testing in one centralized facility will be more efficient than performing these tasks in individual laboratories, as it will allow automation of each step by the use of Beckman Biomek 2000 robotic arms and multiplex PCR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-24S2
Application #
6217269
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Yao; Hu, Hao; Chen, Jiun-Sheng et al. (2018) Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes. Biochim Biophys Acta Mol Basis Dis 1864:2247-2254
Melancon, Marites P; Appleton Figueira, Tomas; Fuentes, David T et al. (2018) Development of an Electroporation and Nanoparticle-based Therapeutic Platform for Bone Metastases. Radiology 286:149-157
Zhao, Hui; Zhang, Ning; Ho, Vivian et al. (2018) Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124:679-687
Pan, Hubert Y; Jiang, Jing; Hoffman, Karen E et al. (2018) Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol 36:1823-1830
Grossberg, Aaron J; Mohamed, Abdallah S R; Elhalawani, Hesham et al. (2018) Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data 5:180173
Lu, Zhimin; Hunter, Tony (2018) Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci 43:301-310
Beadnell, Thomas C; Nassar, Kelsey W; Rose, Madison M et al. (2018) Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 7:23
Chen, Xiuhui; Mangala, Lingegowda S; Rodriguez-Aguayo, Cristian et al. (2018) RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37:107-124
Kono, Miho; Fujii, Takeo; Matsuda, Naoko et al. (2018) Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. J Cancer 9:3640-3646
Khouri, Issa F; Fernandez Curbelo, Irina; Turturro, Francesco et al. (2018) Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24:1011-1018

Showing the most recent 10 out of 12418 publications